Developer docs
API playgroundTry for free, no card

Search company profiles

Zetta Genomics

Full company profile

uuid0002i2z

Namestring
Zetta Genomics
Legal namestring
Zetta Genomics Limited
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Zetta Genomics is a UK-based genomic data management company founded in 2018 as a spin-out from the University of Cambridge and Genomics England. The company developed XetaBase, a genomic-native tertiary analysis platform built on the open-source OpenCB software foundation, which aggregates, stores, retrieves, annotates, visualises, and interprets genomic data at population scale — from single-sample VCF files to hundreds of thousands of whole genomes. The platform supports multi-omics including whole genome/exome sequencing, long-read data, transcriptomics, epigenomics, proteomics, and structural variants, with federated architecture enabling decentralised data sharing across borders and institutions.

Zetta serves four primary customer segments: clinical diagnostics organisations, national and regional healthcare initiatives (including the NHS Genomics Medicine Service and newborn screening), biopharmaceutical companies for biomarker and therapeutic discovery, and academic research institutions. Named customers include Genomics England, NHS, Children's Hospital of Los Angeles, SJD Barcelona, MRC Human Genetics Unit at the University of Edinburgh, and TriNetX. The company holds MHRA registration with UKCA marking and ISO 27001 Stage 2 certification, positioning it for regulated clinical deployments.

The business operates on a quote-based enterprise subscription model with platform licensing of XetaBase as the core revenue stream, complemented by managed services, SaaS products distributed through AWS and Azure Marketplaces, and clinical integration services. Distribution combines direct enterprise field sales (led by a CRO and CCO) with channel partnerships (IBM, GBM, Gulf Scientific) and marketplace listings. The company raised approximately £6.2 million across three seed rounds between 2022 and 2024, with offices in Cambridge (UK) and Valencia (Spain). In April 2026, TriNetX acquired key Zetta assets including the XetaBase platform.

Short descriptiontext

Zetta Genomics is a UK-based genomic data management company offering the XetaBase platform for population-scale tertiary analysis of genomic and multi-omic data, serving clinical diagnostics, national healthcare initiatives, biopharmaceutical firms, and research institutions globally.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCambridge, United Kingdom
HQ citystring
Cambridge
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
genomic data management, clinical genomics software, multiomics data platform, variant annotation services, population genomics platform
Industry4 codes
PRIMARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGANAI
Bioinformatics, Multi-Omics Data Analysis & Interpretation Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code3 codes
  • Software Publishers5132
  • Custom Computer Programming Services541511
  • Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services5182
SIC code1 code
  • Services-Computer Programming Services7371
Product category
Genomic Data Management Software
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model4 records
1Platform Licensing (XetaBase)
TypeSubscription Recurring
Description

Licensing of XetaBase genomic data management platform to healthcare systems, research institutions, and life sciences companies for managing and analysing genomic data.

zettagenomics.com
2SaaS Products (AWS/Azure Marketplace)
TypeSubscription Recurring
Description

Cloud-based SaaS variant store and annotation store products available through AWS Marketplace and Azure Marketplace, providing scalable genomic data storage and analysis as a service.

zettagenomics.com
3Managed Services
TypeManaged Services
Description

First managed service customer onboarded in 2019, providing ongoing managed service support for genomic data management.

zettagenomics.com
4Clinical Integrations
TypeProfessional Services
Description

Streamlined connectivity with EHRs, LIMS, reporting tools and downstream clinical systems, enabling genomics to flow into clinical decision pathways.

zettagenomics.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales
Pricing details1 tier
1Enterprise Platform Licensing
ModelSubscriptionBilling cadenceAnnual
Notes

Quote-based pricing for XetaBase platform licensing to healthcare systems, research institutions and biopharma companies.

zettagenomics.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Zetta Genomics develops and sells XetaBase, a genomic-native tertiary analysis platform that aggregates, integrates, stores, retrieves, annotates, visualizes, analyzes, and interprets large-scale genomic and multi-omics data. Built on the open-source OpenCB platform, the software scales from single-sample VCF to hundreds of thousands of whole genomes, serving clinical diagnostics labs, healthcare population genomics programs, biopharma companies, and research institutions. The company also offers SaaS Variant Store and Annotation Store products via AWS Marketplace.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Scales to 500,000 genomes under management
+4 more records
Product overview1 text field

Zetta Genomics offers a unified genomic data management platform centered on XetaBase, built on the open-source OpenCB software. The product portfolio includes the core XetaBase platform for tertiary genomic analysis, supplemented by specialised modules including the Xeta Variant Store and Xeta Variant Annotation Store for SaaS deployment on AWS, and CellBase for integrated knowledge and annotation. Solutions are segmented by industry vertical: Clinical Diagnostics, Healthcare Initiatives, Biopharmaceutical, and Research Institutions. The platform handles genomic data aggregation, storage, retrieval, annotation, visualisation, and interpretation at population scale, supporting both cloud-native and on-premises deployment with full clinical workflow automation capabilities.

Product and service3 records
1XetaBase
CategoryGenomic data management platform
Description

A genomic-native tertiary analysis platform built on open-source OpenCB software that aggregates, integrates, stores, retrieves, annotates, visualizes, analyses and interprets genomic data at population scale. Supports both research and clinical applications with cloud-native and on-premises deployment options, scaling from single sample VCF to hundreds of thousands of whole genomes. Target users are clinical diagnostic laboratories, healthcare population genomics programmes, biopharma companies, and research institutions.

2Xeta Variant Store
CategoryVariant storage software (SaaS)
Description

A secure, high-performance cloud-native repository for genomic variant data, built to handle population-scale volumes with harmonised, query-ready data structures supporting fast clinical interpretation, cohort analysis, and downstream discovery. Delivered as SaaS on AWS Marketplace and targeted at enterprise customers requiring managed variant storage at scale.

3Xeta Variant Annotation Store
CategoryVariant annotation software (SaaS)
Description

A SaaS-based annotation engine that cross-references variants against multiple genomic knowledge bases, continuously updated and integrated via APIs with 60+ annotation databases. Designed for enterprise clinical and research teams that need to ensure they work from the most current and clinically relevant evidence with automated enrichment and real-time updates.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership11 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-07
Description

World's leading federated health data network. Collaboration since 2024 on federated querying across genomic and phenotypic data. TriNetX acquired key Zetta assets including XetaBase platform in April 2026 to expand multiomic capabilities.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-02-08
Description

Strategic partnership with Microsoft as part of industry leaders collaboration. XetaBase platform integration and expansion plans through Microsoft ecosystem.

3Fujitsu
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-02-08
Description

Strategic partnership with Fujitsu for industry collaboration and market expansion in healthcare technology sector.

finsmes.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-02-08
Description

Strategic partnership with IQVIA for healthcare industry collaboration, bringing genomic data capabilities to pharmaceutical and healthcare clients.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-01-01
Description

Zetta Genomics spun out from University of Cambridge in 2018. Ignacio Medina serves as Head of Computational Biology Lab at Cambridge Research Computing Service.

Strategic tierMinorTypeGTM or Marketing Partner
Description

IBM Watson Discovery integration mentioned. IBM partners able to demonstrate Zetta products at PMFG Sidra Conference.

Strategic tierMinorTypeGTM or Marketing Partner
Description

Regional partner for Gulf region able to demonstrate Zetta products and discuss partnership at PMFG Sidra Conference.

Strategic tierMinorTypeGTM or Marketing Partner
Description

Regional partner for Middle East able to demonstrate Zetta products and discuss partnership at PMFG Sidra Conference.

Strategic tierCoreTypeTechnology or Integration
Description

AWS Marketplace listing for SaaS Variant Store and Annotation Store products. Zetta positioned as preferred partner following AWS HealthOmics closure to new customers. XetaBase launched on AWS alongside Azure.

10Azure (Microsoft)
Strategic tierCoreTypeTechnology or Integration
Description

Azure Marketplace listing for XetaBase platform. Cloud deployment option alongside AWS for customers preferring Microsoft cloud infrastructure.

zettagenomics.com
11Genomics England
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Zetta Genomics spun out from Genomics England. XetaBase originally inspired by challenges encountered during 100,000 Genomes Project. Technology proven at scale in flagship population genomics project.

zettagenomics.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

DNAnexus provides a cloud-based genomic and biomedical data management and analysis platform serving clinical, research and pharmaceutical customers. It is the closest direct peer to Zetta's XetaBase in scale, deployment model and target customer base.

TypeDirect peer
Description

SOPHiA Genetics operates a clinical genomics platform using AI to analyse multiomic data for hospitals and labs. It competes head-to-head with XetaBase in clinical variant interpretation; Zetta NED Bram Goorden is an SOPHiA alumnus.

TypeDirect peer
Description

Congenica provides clinical genomic data interpretation software for rare disease and cancer diagnostics. It is a direct peer in the clinical tertiary analysis category; Zetta's Head of Product previously worked at Congenica.

TypeDirect peer
Description

BC Platforms offers genomic and clinical data management infrastructure with a focus on federated data and real-world evidence. It is a direct peer in population-scale genomics platforms and federated data sharing.

TypeDirect peer
Description

WuXi NextCODE built a genomics data and analytics platform used for clinical trial sequencing and population genomics. Zetta CCO Mark Hughes led large-scale clinical trial sequencing projects at WuXi NextCODE, and the companies compete for similar biopharma accounts.

TypeDirect peer
Description

Lifebit provides a federated genomics and biomedical data platform with Trusted Research Environments. It is a direct peer in the federated, cloud-native tertiary analysis category, particularly for national genomics initiatives.

TypeDirect peer
Description

Fabric Genomics (now part of GeneDx) provides AI-driven clinical genomic interpretation software. It is a direct peer in clinical tertiary analysis and variant interpretation for hospital and reference-lab customers.

TypeBroad incumbent
Description

Illumina is the dominant sequencing instrument vendor and increasingly offers cloud-based genomic data management and analytics through Illumina Connected Analytics and DRAGEN. It is a broad incumbent that competes on the platform layer in addition to sequencing.

9PierianDx (now part of Elsevier)
TypeDirect peer
Description

PierianDx provided a clinical genomics interpretation platform for hospital labs before being acquired by Elsevier. It was a direct peer in clinical tertiary analysis, EHR integration and variant interpretation workflows.

10Genomics England
TypeOthers
Description

Genomics England delivered the 100,000 Genomes Project and now operates the NHS Genomic Medicine Service. It is both a Zetta partner/customer and a public-sector reference customer whose internal data platform strategy shapes Zetta's UK opportunity.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
Yes

Docs URL, Description

Integration3 records

Each record includes

Title, Type, Description, Source

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature10 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Zetta Genomics

Genomic Data Management Softwarezettagenomics.com

Zetta Genomics is a UK-based genomic data management company offering the XetaBase platform for population-scale tertiary analysis of genomic and multi-omic data, serving clinical diagnostics, national healthcare initiatives, biopharmaceutical firms, and research institutions globally.

What Zetta Genomics does

Zetta Genomics is a UK-based genomic data management company founded in 2018 as a spin-out from the University of Cambridge and Genomics England. The company developed XetaBase, a genomic-native tertiary analysis platform built on the open-source OpenCB software foundation, which aggregates, stores, retrieves, annotates, visualises, and interprets genomic data at population scale — from single-sample VCF files to hundreds of thousands of whole genomes. The platform supports multi-omics including whole genome/exome sequencing, long-read data, transcriptomics, epigenomics, proteomics, and structural variants, with federated architecture enabling decentralised data sharing across borders and institutions.

Zetta serves four primary customer segments: clinical diagnostics organisations, national and regional healthcare initiatives (including the NHS Genomics Medicine Service and newborn screening), biopharmaceutical companies for biomarker and therapeutic discovery, and academic research institutions. Named customers include Genomics England, NHS, Children's Hospital of Los Angeles, SJD Barcelona, MRC Human Genetics Unit at the University of Edinburgh, and TriNetX. The company holds MHRA registration with UKCA marking and ISO 27001 Stage 2 certification, positioning it for regulated clinical deployments.

The business operates on a quote-based enterprise subscription model with platform licensing of XetaBase as the core revenue stream, complemented by managed services, SaaS products distributed through AWS and Azure Marketplaces, and clinical integration services. Distribution combines direct enterprise field sales (led by a CRO and CCO) with channel partnerships (IBM, GBM, Gulf Scientific) and marketplace listings. The company raised approximately £6.2 million across three seed rounds between 2022 and 2024, with offices in Cambridge (UK) and Valencia (Spain). In April 2026, TriNetX acquired key Zetta assets including the XetaBase platform.

Zetta Genomics firmographics

Firmographics
Name
Zetta Genomics
Legal name
Zetta Genomics Limited
Website
https://zettagenomics.com
Company type
Private
Founded year
2018
Operating status
Acquired
Headcount range
11–50 employees
Short description
Zetta Genomics is a UK-based genomic data management company offering the XetaBase platform for population-scale tertiary analysis of genomic and multi-omic data, serving clinical diagnostics, national healthcare initiatives, biopharmaceutical firms, and research institutions globally.
Ownership category
akta.pro rank

Zetta Genomics industry classification

Industry
Product category
Genomic Data Management Software
NAICS
Software Publishers (5132), Custom Computer Programming Services (541511), Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services (5182)
SIC
Services-Computer Programming Services (7371)
akta.pro industry
PRIMARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGANAI
Bioinformatics, Multi-Omics Data Analysis & Interpretation Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Genomic data management
  • Clinical genomics software
  • Multiomics data platform
  • Variant annotation services
  • Population genomics platform

Where Zetta Genomics is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

Zetta Genomics business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales

Revenue model

  1. Platform Licensing (XetaBase): Licensing of XetaBase genomic data management platform to healthcare systems, research institutions, and life sciences companies for managing and analysing genomic data.
  2. SaaS Products (AWS/Azure Marketplace): Cloud-based SaaS variant store and annotation store products available through AWS Marketplace and Azure Marketplace, providing scalable genomic data storage and analysis as a service.
  3. Managed Services: First managed service customer onboarded in 2019, providing ongoing managed service support for genomic data management.
  4. Clinical Integrations: Streamlined connectivity with EHRs, LIMS, reporting tools and downstream clinical systems, enabling genomics to flow into clinical decision pathways.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualEnterprise Platform Licensing

Go-to-market motion4 records

Distribution channels4 records

Marketing channels8 records

Zetta Genomics product offering

Product offering

Core offering

Zetta Genomics develops and sells XetaBase, a genomic-native tertiary analysis platform that aggregates, integrates, stores, retrieves, annotates, visualizes, analyzes, and interprets large-scale genomic and multi-omics data. Built on the open-source OpenCB platform, the software scales from single-sample VCF to hundreds of thousands of whole genomes, serving clinical diagnostics labs, healthcare population genomics programs, biopharma companies, and research institutions. The company also offers SaaS Variant Store and Annotation Store products via AWS Marketplace.

Product overview

Zetta Genomics offers a unified genomic data management platform centered on XetaBase, built on the open-source OpenCB software. The product portfolio includes the core XetaBase platform for tertiary genomic analysis, supplemented by specialised modules including the Xeta Variant Store and Xeta Variant Annotation Store for SaaS deployment on AWS, and CellBase for integrated knowledge and annotation. Solutions are segmented by industry vertical: Clinical Diagnostics, Healthcare Initiatives, Biopharmaceutical, and Research Institutions. The platform handles genomic data aggregation, storage, retrieval, annotation, visualisation, and interpretation at population scale, supporting both cloud-native and on-premises deployment with full clinical workflow automation capabilities.

Differentiator

Problem solved

Functional benefit

Products and services

  • XetaBase A genomic-native tertiary analysis platform built on open-source OpenCB software that aggregates, integrates, stores, retrieves, annotates, visualizes, analyses and interprets genomic data at population scale. Supports both research and clinical applications with cloud-native and on-premises deployment options, scaling from single sample VCF to hundreds of thousands of whole genomes. Target users are clinical diagnostic laboratories, healthcare population genomics programmes, biopharma companies, and research institutions.
  • Xeta Variant Store A secure, high-performance cloud-native repository for genomic variant data, built to handle population-scale volumes with harmonised, query-ready data structures supporting fast clinical interpretation, cohort analysis, and downstream discovery. Delivered as SaaS on AWS Marketplace and targeted at enterprise customers requiring managed variant storage at scale.
  • Xeta Variant Annotation Store A SaaS-based annotation engine that cross-references variants against multiple genomic knowledge bases, continuously updated and integrated via APIs with 60+ annotation databases. Designed for enterprise clinical and research teams that need to ensure they work from the most current and clinically relevant evidence with automated enrichment and real-time updates.

Quantifiable outcome

  • Scales to 500,000 genomes under management
  • +4 more outcomes

Companies that use Zetta Genomics

Customer profile

Named customers6 records

Segments4 records

Ideal customer profiles4 records

Zetta Genomics technology and API

Technology

Technology focussed Yes

API detail

Has API
Yes
API docs
API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability5 records

Feature10 records

Zetta Genomics partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered core and minor.

  • TriNetXcoreStrategic or Co-development Partner · 7 April 2026World's leading federated health data network. Collaboration since 2024 on federated querying across genomic and phenotypic data. TriNetX acquired key Zetta assets including XetaBase platform in April 2026 to expand multiomic capabilities.
  • MicrosoftcoreStrategic or Co-development Partner · 8 February 2024Strategic partnership with Microsoft as part of industry leaders collaboration. XetaBase platform integration and expansion plans through Microsoft ecosystem.
  • FujitsucoreStrategic or Co-development Partner · 8 February 2024Strategic partnership with Fujitsu for industry collaboration and market expansion in healthcare technology sector.
  • IQVIAcoreStrategic or Co-development Partner · 8 February 2024Strategic partnership with IQVIA for healthcare industry collaboration, bringing genomic data capabilities to pharmaceutical and healthcare clients.
  • University of CambridgecoreStrategic or Co-development Partner · 1 January 2018Zetta Genomics spun out from University of Cambridge in 2018. Ignacio Medina serves as Head of Computational Biology Lab at Cambridge Research Computing Service.
  • IBMminorGTM or Marketing PartnerIBM Watson Discovery integration mentioned. IBM partners able to demonstrate Zetta products at PMFG Sidra Conference.
  • GBM (Gulf Business Machines)minorGTM or Marketing PartnerRegional partner for Gulf region able to demonstrate Zetta products and discuss partnership at PMFG Sidra Conference.
  • Gulf ScientificminorGTM or Marketing PartnerRegional partner for Middle East able to demonstrate Zetta products and discuss partnership at PMFG Sidra Conference.
  • AWS (Amazon Web Services)coreTechnology or IntegrationAWS Marketplace listing for SaaS Variant Store and Annotation Store products. Zetta positioned as preferred partner following AWS HealthOmics closure to new customers. XetaBase launched on AWS alongside Azure.
  • Azure (Microsoft)coreTechnology or IntegrationAzure Marketplace listing for XetaBase platform. Cloud deployment option alongside AWS for customers preferring Microsoft cloud infrastructure.
  • Genomics EnglandcoreStrategic or Co-development PartnerZetta Genomics spun out from Genomics England. XetaBase originally inspired by challenges encountered during 100,000 Genomes Project. Technology proven at scale in flagship population genomics project.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

Zetta Genomics competitors and assessment

Company assessment

Direct peers

  • DNAnexus: DNAnexus provides a cloud-based genomic and biomedical data management and analysis platform serving clinical, research and pharmaceutical customers. It is the closest direct peer to Zetta's XetaBase in scale, deployment model and target customer base.
  • SOPHiA Genetics: SOPHiA Genetics operates a clinical genomics platform using AI to analyse multiomic data for hospitals and labs. It competes head-to-head with XetaBase in clinical variant interpretation; Zetta NED Bram Goorden is an SOPHiA alumnus.
  • Congenica: Congenica provides clinical genomic data interpretation software for rare disease and cancer diagnostics. It is a direct peer in the clinical tertiary analysis category; Zetta's Head of Product previously worked at Congenica.
  • BC Platforms: BC Platforms offers genomic and clinical data management infrastructure with a focus on federated data and real-world evidence. It is a direct peer in population-scale genomics platforms and federated data sharing.
  • WuXi NextCODE (now Genuity Science): WuXi NextCODE built a genomics data and analytics platform used for clinical trial sequencing and population genomics. Zetta CCO Mark Hughes led large-scale clinical trial sequencing projects at WuXi NextCODE, and the companies compete for similar biopharma accounts.
  • Lifebit Biotech: Lifebit provides a federated genomics and biomedical data platform with Trusted Research Environments. It is a direct peer in the federated, cloud-native tertiary analysis category, particularly for national genomics initiatives.
  • Fabric Genomics (GeneDx): Fabric Genomics (now part of GeneDx) provides AI-driven clinical genomic interpretation software. It is a direct peer in clinical tertiary analysis and variant interpretation for hospital and reference-lab customers.
  • PierianDx (now part of Elsevier): PierianDx provided a clinical genomics interpretation platform for hospital labs before being acquired by Elsevier. It was a direct peer in clinical tertiary analysis, EHR integration and variant interpretation workflows.

Broad incumbents

  • Illumina (Connected Software / Illumina Connected Analytics): Illumina is the dominant sequencing instrument vendor and increasingly offers cloud-based genomic data management and analytics through Illumina Connected Analytics and DRAGEN. It is a broad incumbent that competes on the platform layer in addition to sequencing.

Others

  • Genomics England: Genomics England delivered the 100,000 Genomes Project and now operates the NHS Genomic Medicine Service. It is both a Zetta partner/customer and a public-sector reference customer whose internal data platform strategy shapes Zetta's UK opportunity.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Zetta Genomics social profiles

Digital presence

Zetta Genomics compliance and trust

Trust signal

Compliance4 records

Zetta Genomics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Zetta Genomics leadership team

Management profile

Number of profiles

Profiles10 records

Zetta Genomics funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Zetta Genomics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Zetta Genomics

What does Zetta Genomics do?

Zetta Genomics develops and sells XetaBase, a genomic-native tertiary analysis platform that aggregates, integrates, stores, retrieves, annotates, visualizes, analyzes, and interprets large-scale genomic and multi-omics data. Built on the open-source OpenCB platform, the software scales from single-sample VCF to hundreds of thousands of whole genomes, serving clinical diagnostics labs, healthcare population genomics programs, biopharma companies, and research institutions. The company also offers SaaS Variant Store and Annotation Store products via AWS Marketplace.

Is Zetta Genomics a public or private company?

Zetta Genomics is a private company. It is classified as venture growth investor backed and is currently acquired.

When was Zetta Genomics founded?

Zetta Genomics was founded in 2018. It employs 11 to 50 people.

Where is Zetta Genomics based?

Zetta Genomics is headquartered in Cambridge, United Kingdom, in the Europe region.

How does Zetta Genomics make money?

Four revenue lines are on record. Platform Licensing (XetaBase) is the primary driver. The others are saaS Products (AWS/Azure Marketplace), managed Services and clinical Integrations.

Who are Zetta Genomics's main competitors?

Direct peers on record are DNAnexus, SOPHiA Genetics, Congenica, BC Platforms, WuXi NextCODE (now Genuity Science), Lifebit Biotech, Fabric Genomics (GeneDx) and PierianDx (now part of Elsevier). Illumina (Connected Software / Illumina Connected Analytics) is listed as a broad incumbent. Genomics England is listed as an others.

Does Zetta Genomics have an API?

Yes. XetaBase provides comprehensive REST APIs enabling integration with existing pipelines and cloud infrastructure. Official client libraries are available for Python, R, Java, and JavaScript. The platform also offers its own command line interface and extensive web services for programmatic access. Developer documentation is at zettagenomics.com/documentation.

What industry is Zetta Genomics in?

Zetta Genomics's product category is Genomic Data Management Software. Its primary akta.pro industry code is HLAGAJAD, Bioinformatics & Multi-omics Analysis Software, with a secondary code of HLAGANAI, Bioinformatics, Multi-Omics Data Analysis & Interpretation Services. Its NAICS code is 5132 and its SIC code is 7371.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Pulse 2.0TriNetX: Acquisition Of Zetta Genomics Assets To Expand Multiomic Data CapabilitiesTriNetX announced the acquisition of key assets from Zetta Genomics, strengthening its genomic data federation and analysis capabilities across its global healthcare provider network. The deal integrates Zetta's flagship XetaBase platform, which enables population-scale genomic analysis, into TriNetX's ecosystem to enhance multiomic data combining phenotypic and genomic information. The acquisition builds on a partnership established in 2024 and is expected to help life sciences customers conduct large-scale research more efficiently while maintaining data privacy within originating healthcare institutions.Business WeeklyTriNetX swallows Zetta Genomics in transatlantic dealTriNetX has acquired Zetta Genomics in a transatlantic deal that expands TriNetX's genomics data management and analytics capabilities, specifically adding Zetta's XetaBase multiomic capture and analytics platform to its ecosystem. The companies had been collaborating since 2024 on federated querying across genomic and phenotypic data, demonstrating technical feasibility for secure, scalable data integration serving healthcare providers, life sciences companies, and research institutes. The acquisition is intended to accelerate healthcare providers' ability to integrate phenotypic and multiomic data for improved care delivery and clinical research at population scale.PR NewswireTriNetX renforce sa capacité à fédérer les données génomiques dans son réseau mondial de fournisseurs grâce à l'acquisition d'actifs clés de Zetta GenomicsTriNetX, the world's leading federated health data network, has acquired key assets from Zetta Genomics, a Cambridge, UK-based health technology company and former partner. The acquisition integrates Zetta's XetaBase platform, a multiomic data capture and analysis solution, into TriNetX's ecosystem, strengthening its genomic data management capabilities. The deal enables healthcare providers to integrate multiomic and phenotypic data for improved clinical research and patient care, while expanding TriNetX's global reach in federated health data research.National TodayTriNetX Acquires Key Assets of Zetta Genomics to Enhance Genomics Data CapabilitiesTriNetX, a leading health research network, announced on April 7, 2026 the acquisition of key assets from Zetta Genomics, a company specializing in genomics data management and analytics. The deal centers on Zetta's award-winning XetaBase technology platform for managing and analyzing genomics data, which will be integrated into TriNetX's global health research network. The acquisition enables TriNetX to enhance its capacity to support research and personalized patient care by providing more comprehensive genomics data capabilities to healthcare providers and biopharma clients.AijournTriNetX Enhances its Ability to Federate Genomics Data Across its Global Network of Providers through the Acquisition of Key Assets of Zetta GenomicsTriNetX, the world's leading federated health data network, has acquired the key assets of Zetta Genomics, a Cambridge, UK-based healthcare technology company and existing TriNetX partner. The acquisition brings Zetta's XetaBase multiomic capture and analytics platform into TriNetX's ecosystem, expanding its genomics data management capabilities for healthcare providers and life sciences customers. The two companies had collaborated since 2024 on technical feasibility work demonstrating secure, federated querying across genomic and phenotypic data.PR NewswireTriNetX erweitert durch die Übernahme der wichtigsten Vermögenswerte von Zetta Genomics seine Fähigkeit, Genomikdaten über sein globales Netzwerk von Anbietern zu bündelnTriNetX, the global federated health data network headquartered in Cambridge, Massachusetts, has acquired the key assets of Zetta Genomics, a Cambridge, UK-based health technology company and existing partner. The acquisition adds Zetta's XetaBase platform—a Multi-Omics data capture and analysis platform designed for population genome analysis—to TriNetX's ecosystem, enhancing its genomics data management and analytics capabilities. TriNetX and Zetta have collaborated since 2024 within TriNetX's genomics data program, conducting technical feasibility studies demonstrating secure, federated querying of genomic and phenotypic data.PR NewswireTriNetX Enhances its Ability to Federate Genomics Data Across its Global Network of Providers through the Acquisition of Key Assets of Zetta GenomicsTriNetX, the world's leading federated health data network, announced the acquisition of key assets of Zetta Genomics, a Cambridge, UK-based healthcare technology company and existing partner, for an undisclosed amount. The acquisition brings Zetta's flagship XetaBase multiomic capture and analytics platform into TriNetX's portfolio, expanding its genomics data management capabilities and enabling healthcare providers to integrate phenotypic and multiomic data for improved care delivery and clinical research. The two companies had collaborated since 2024 on technical feasibility work demonstrating secure, federated querying across genomic and phenotypic data at scale.NewswireTriNetX Enhances its Ability to Federate Genomics Data Across its Global Network of Providers through the Acquisition of Key Assets of Zetta GenomicsTriNetX, the world's leading federated health data network, has acquired the key assets of Zetta Genomics, a Cambridge, UK-based healthcare technology company and existing partner. The acquisition brings Zetta's XetaBase multiomic capture and analytics platform into TriNetX's ecosystem, expanding TriNetX's genomics data management capabilities and supporting federated capture of multiomic data for healthcare providers and life sciences research. The integration is expected to accelerate healthcare providers' ability to integrate phenotypic and multiomic data for improved care delivery and clinical research.TrinetxTriNetX Enhances its Ability to Federate Genomics Data Across its Global Network of Providers through the Acquisition of Key Assets of Zetta GenomicsTriNetX has acquired key assets of Zetta Genomics, a Cambridge, UK-based healthcare technology company, to expand its genomics data management and analytics capabilities. The acquisition brings Zetta's flagship XetaBase multiomic capture and analytics platform into TriNetX's ecosystem, supporting federated capture of multiomic data for healthcare providers and life sciences customers. The two companies had collaborated since 2024 as part of TriNetX's genomics data program, completing technical feasibility work on secure federated querying across genomic and phenotypic data.BioSpaceTriNetX Enhances its Ability to Federate Genomics Data Across its Global Network of Providers through the Acquisition of Key Assets of Zetta GenomicsTriNetX, the world's leading federated health data network, announced it has acquired the key assets of Zetta Genomics, a Cambridge, UK-based healthcare technology company and existing partner. The acquisition integrates Zetta's flagship XetaBase multiomic capture and analytics platform into TriNetX's ecosystem, expanding its genomics data management and analytics capabilities for population-scale genomic analysis. The companies had collaborated since 2024, completing technical feasibility work demonstrating secure, federated querying across genomic and phenotypic data.